healthcare innovation summit 2016

Global Hospital & Healthcare Management

 

 

 

Saturday
Jul 23rd
  • Bookmark and Share
  • Login
  • Sign up
    Registration
    Fields marked with an asterisk (*) are required.
    Name: *
    Username: *
    E-mail: *
    Password: *
    Verify Password: *
    Company name: *
    Position:
    Telephone:
  • Search
Text size
  • Increase font size
  • Default font size
  • Decrease font size
Featured Articles
  • Pause
  • Previous
  • Next
1/15
 
Sandoz' Enbrel biosimilar shows equivalent efficacy to originator product (06.07.2016)
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
 
The study compared the safety and efficacy of its biosimilar etanercept candidate with the originator product, Enbrel® in patients with moderate-to-severe chronic plaque-type psoriasis and was presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network (PIN), Paris, France.
 
"The EGALITY data, showing our biosimilar etanercept to be bioequivalent to the originator product, is part of the comprehensive data package submitted to the EMA and FDA" said Malte Peters, Head Global Clinical Development, Biopharmaceuticals, Sandoz. "If our biosimilar etanercept is approved for the same indications as the originator product, more patients with chronic inflammatory conditions like rheumatoid arthritis and psoriasis will have access to life-changing biologic treatment options" Peters continued.
 
Additional data from the study confirms similarity between the biosimilar etanercept candidate and the originator product in terms of safety and immunogenicity; the incidence of adverse events at week 12 was comparable.
 
"The EGALITY study is a landmark in clinical trial design. Data has been collected from over 500 patients in one year with multiple treatment switches where a patient receives either the biosimilar etanercept candidate or the originator product on a number of alternate occasions," said Professor Diamant Thaçi, Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, Lubeck. "Data from this study, in addition to analytical, functional and pre-clinical studies, provides confidence in the comprehensive data package that is the basis for biosimilar medicine approval and use by healthcare practitioners." Thaçi continued.
 
Sandoz announced that its biosimilar etanercept candidate was accepted by the EMA and FDA for regulatory review in the second half of 2015. Sandoz is seeking approval for all indications included in the label of the originator product, which is used to treat various inflammatory conditions, including rheumatoid arthritis and psoriasis. 
 
Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global leader in biosimilars and currently markets three biosimilars. Sandoz has a leading biosimilar pipeline and plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020. This will be enabled by 11 filings over a three-year period (2015-2017) having already submitted six and had one approved. As a division of the Novartis Group, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization.
 
About the EGALITY study
(Psoriasis 2016, 5th Congress of the Psoriasis International Network (PIN) (PSO2016 ref: LATEABS-1325)
The EGALITY study was a randomized, double-blind trial involving 531 patients and carried out in 74 dermatology clinics in 11 European countries and South Africa (NCT01891864). It compared the efficacy and safety of Sandoz etanercept biosimilar candidate with the originator product Enbrel®. The primary endpoint was equivalence in PASI 75 response rates after the first 12 weeks' treatment. Key secondary efficacy endpoints at week 12 were based on percent change from baseline in PASI, clinical safety and immunogenicity.
 
About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.*European Medicines Agency (EMA)

References
1. Griffiths EM, et al. GP2015, a proposed etanercept biosimilar, has equivalent efficacy, safety and immunogenicity to etanercept originator product in patients with chronic plaque-type psoriasis: 12 week results from the phase 3 EGALITY study. Poster presented at the Psoriasis 2016, 5th Congress of the Psoriasis International Network (PIN), July 07, 2016 (e-poster P222)

Novartis Global Media Relations
e-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Eric Althoff
Novartis Global Media Relations
+41-61-324-7999
+41-79-593-4202
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Tara Lanigan
Sandoz Global Communications
+49 (0) 172 8295 276
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 
Duncan Cantor
Sandoz Global Communications
+49 (0) 170 650 6067
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 
Novartis Investor Relations 

Central phone:
+41 61 324 7944
 
Samir Shah
+41 61 324 7944
 
Pierre-Michel Bringer
+41 61 324 1065
 
Thomas Hungerbuehler
+41 61 324 8425
 
Isabella Zinck
+41 61 324 7188
 
North America:  
Richard Pulik
+1 212 830 2448
 
Sloan Pavsner
+1 212 830 2417
e-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it


Read more...
CVS Health Institute Study Shows that Medication Reconciliation Can Reduce Hospital Readmissions (06.07.2016)

A new study from the CVS Health Research Institute found that medication reconciliation programs, in which pharmacists review patients' medication regimens and provide adherence counseling during the patient's transition from hospital to home, reduced risk of hospital readmission by 50 percent and helped avoid unnecessary health care costs. The research, published today in the July issue of Health Affairs, is the first to evaluate the impact of an insurer-supported medication reconciliation program on clinical outcomes and health care spending.

"After leaving the hospital people are especially vulnerable and are often dealing with complex and changing care regimens, which can result in high rates of medication non-adherence and increased risk for costly and unnecessary readmissions," said Troyen A. Brennan, M.D., executive vice president and Chief Medical Officer, CVS Health. "In fact, adverse drug events, often attributable to medication non-adherence, are associated with the majority of hospital readmissions. This research shows that programs that provide patients with additional support from a pharmacist can help improve health outcomes and save payers and patients money."

The study analyzed hospital readmissions of more than 260 members of a national health plan who were hospitalized over a five-month period. Researchers compared readmission rates for patients enrolled in a medication reconciliation program upon hospital discharge to a control group of members who received no additional support following their initial hospital stay. Those enrolled in the program received an initial in-home or telephonic consultation based on their readmission risk and were also offered ongoing telephonic support for the first 30 days following discharge.

During the initial consultations, pharmacists compared members' pre- and post- hospitalization medication regimens; identified discrepancies, redundancies and safety concerns; and provided education and support regarding medication use and adherence. The researchers found that risk of hospital readmission at 30 days was reduced by 50 percent, reducing overall risk of hospital readmission from 22 percent to 11 percent for those in the medication reconciliation program. Additionally, the health plan saved $2 for every $1 spent on the program, resulting in a total savings of more than $1300 per member.

"The research found that the positive effects of the pharmacist consultation on reducing readmission rates and costs were similar whether the consultation was conducted via an in-home visit from a pharmacist or over the telephone when the intensity of the intervention was tailored to members' risk," added Dr. Brennan. "These results demonstrate that there is an opportunity for payers to consider adopting programs that provide pharmacist support and counseling by phone as a cost-efficient way to help improve medication adherence and health outcomes for their vulnerable populations."

An estimated one in seven patients discharged from a hospital is readmitted within 30 days, and readmissions are associated with more than $41 billion in additional health care costs per year. In addition, evidence suggests that approximately 66 percent of hospital readmissions are the result of adverse health events related to medication non-adherence. Historically, health insurers have had little control over direct efforts to reduce hospital readmission rates for their members. When available, these kinds of programs are largely run by hospitals and outpatient providers and their impact has not been broadly evaluated.

The CVS Health Research Institute is focused on contributing to the body of scientific knowledge related to pharmacy and health care through research collaborations with external academic institutions, participation in federally-funded research, analysis and sharing of CVS Health data sources and coordination of pilot programs and initiatives. CVS Health Research Institute findings support a continuous quality improvement environment, which encourages product innovation and development to benefit CVS Health patients, clients and their members.

About CVS Health
CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 80 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contacts:

Christine Cramer
CVS Health
(401) 770-3317
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Christina Beckerman
CVS Healt
(401) 770-8868
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it


Read more...
UnitedHealthcare Community Plan expands to additional counties (06.07.2016)
UnitedHealthcare Community Plan now serves residents in 60 Wisconsin counties
Plan participants have access to innovative wellness and member-outreach programs, and "Baby Blocks" for expectant mothers and newborns
 
UnitedHealthcare Community Plan has expanded its service area to include four additional Wisconsin counties where it offers health care coverage for individuals and families enrolled in BadgerCare Plus and Medicaid SSI.
 
Effective July 1, 2016, UnitedHealthcare's Community Health Plan is now available in Adams, Columbia, Dane and Sauk counties.
BadgerCare Plus is for pregnant women, children to age 19 and adults who meet income requirements. Medicaid SSI is for Wisconsin residents who receive Supplemental Security Income (SSI) and offers extra support to adults with special health care needs or a disability. These programs offer comprehensive health coverage – including preventive care, primary care, hospitalization, prescriptions and other services often at low or no cost.
 
People enrolled in UnitedHealthcare Community Plans have access to:
  • Wellness programs such as Healthy First Steps, as well as nurse outreach and support for beneficiaries who may need additional assistance in managing chronic diseases including diabetes.
  • "Baby Blocks," a free, online, interactive program designed to help pregnant women and new mothers with prenatal and well-baby care.
  • Additional support through UnitedHealthcare's member-outreach programs that remind and encourage them to seek preventive care.
The four new services areas now bring UnitedHealthcare Community Plan to 60 counties in Wisconsin. They include: Ashland, Barron, Bayfield, Brown, Burnett, Calumet, Chippewa, Crawford, Dodge, Door, Douglas, Eau Claire, Florence, Fond du Lac, Forest, Green, Green Lake, Jefferson, Kenosha, Kewaunee, La Crosse, Langlade, Lincoln, Manitowoc, Marathon, Marinette, Marquette, Menominee, Milwaukee, Monroe, Oconto, Oneida, Outagamie, Ozaukee, Pierce, Polk, Portage, Price, Racine, Rock, Sawyer, Shawano, Sheboygan, St. Croix, Taylor, Trempealeau, Vernon, Vilas, Walworth, Washburn, Washington, Waukesha, Waupaca, Waushara, Winnebago and Wood.
 
"We are grateful for the opportunity to serve more Wisconsin residents by expanding service and providing innovative wellness programs that give people access to affordable, quality health care, particularly preventive care," said Pam Stahl, CEO of UnitedHealthcare Community Plan of Wisconsin. "We look forward to engaging with local health and other community-based organizations as we strive to help improve the health of our members and our communities."
 
To learn more about applying for health insurance, including BadgerCare Plus and Medicaid SSI through the Wisconsin Department of Health Services (DHS), visit www.dhs.wisconsin.gov/forwardhealth/index.htm
 
UnitedHealthcare serves nearly 1.6 million Wisconsin residents with a care provider network of 150 hospitals and more than 28,000 physicians and other health care professionals statewide.
 
About UnitedHealthcare
UnitedHealthcare is dedicated to helping people nationwide live healthier lives by simplifying the health care experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. The company offers the full spectrum of health benefit programs for individuals, employers, military service members, retirees and their families, and Medicare and Medicaid beneficiaries, and contracts directly with 1 million physicians and care professionals, and 6,000 hospitals and other care facilities nationwide. UnitedHealthcare is one of the businesses of UnitedHealth Group , a diversified Fortune 50 health and well-being company. For more information, visit UnitedHealthcare at www.uhc.com  
 
 

Read more...

innovatingcare-ap

WorldHeart

Himss 2016

E-newsletter - latest issue of Hospital & Healthcare Management Newsletter
Please click here to view this newsletter online
Click here to subscribe to our newsletter

M2M communication resulting in new and exciting possibilities in healthcare

The world appears to have shrunk into a virtual ball. People are getting connected through devices; machines are getting connected; and today, even homes are getting connected. Everything in the world is getting connected.

FULL STORY
 
LATEST UPDATE
UPCOMING EVENTS
LATEST UPDATE
 

Effective patient engagement leads hospitals to higher margins & healthy future

Recent Accenture research suggests that hospitals that offer a superior patient experience tend to have 50 percent higher margins than their peers . Hospitals that deliver a superior experience have the opportunity to create happy and healthy patients, as well as a healthy financial future......

FULL STORY
 

Philips Foundation publishes its 2015 Annual Report

The Philips Foundation announced the publication of its 2015 Annual Report which highlights the progress of its global projects with the International Committee of the Red Cross (ICRC), the Netherlands Red Cross and the United Nations Children’...
More:

Philips and SURFsara team up to provide hospitals with ‘Big Data’ research services in the Cloud for

Collaboration combines Philips’ expertise in health informatics and SURFsara’s capabilities in high performance supercomputing infrastructuresVia online portal combined cloud-based services will facilitate multicenter life sciences resear...
More:

Case Study: IBM - i3ARCHIVE

Customeri3ARCHIVEDeployment CountryPennsylvania - USAIndustryHealthcare, Life SciencesSolutionBusiness-to-Business, Business-to-Consumer, Business Performance Transformation, Business Resiliency, Content Management, Data Warehouse, Database Managemen...
More:

Merck to Develop Next-Generation Purification Processes with International Vaccine Institute

Merck, a leading science and technology company, has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop more robust, scalable vaccine manufacturing processes. Merck will provide funding a...
More:

Up Coming Webinars


webners Register through HHM Global for the upcoming webinars conducted by the leading providers covering subjects on various spectrums within the healthcare industry:

  • Webinar Spotlight: Precision Medicine in the Information Age 
  •                - When: On Deman
                     Duration: 1 hour
                     Presented by: Gaurav Singal, MD
                     Director, Innovations Unit Massachusetts General Hospital & Foundation Medicine.
Medical Fair Asia 2016
SUBSCRIPTION
Subscribe for E-Newsletter

Publication

hospital-and-healthcare-management-magazine
June 2016 - PDF | e-book

Discussing about Digitalization in Healthcare & it's benefits have never been more important earlier.

With this in mind, we introduce the latest edition of Hospital & Healthcare Management - Vol 5 Issue 3 your one-stop resource that hepls you stay up to date with the issues that matters most.

View Previous Issues:
Feb'16 | Aug'15 | Feb'15 | Aug'14 | Feb'14 | June'13 | Feb.'13 | Aug.'12 | Apr.'12 | Dec.'11 | Aug.'11 | >> 

Product Showcase

 

Online Medical Records Vault by Sajix Inc

Sajix Inc come up with this unique and revolutionary offering- OMR Vault - iHelix’s Personal H...

 

Flowline Worlds only Servo controlled High Frequency Oscillatory Ventilator DRAGONFLY

WORLDS Only SERVO Controlled High Frequency Oscillatory Ventilator (HFOV) Model DRAGONFLY Features: ...
Advertisement

Feedback Form
Real Time Web Analytics